by Rod Raynovich | Apr 18, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Even the biotech bulls bailed today on the double whammy of concern about Europe’s debt crisis and the S&P echoing the Tea Party refrain about the U.S. budget deficit and need for fiscal reform. As of mid-day trading both the S&P 500 and the NASDAQ is...
by Rod Raynovich | Apr 15, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Drug and Biotechnology Stocks Up Across the Spectrum Its “groundhog day” in biotech world. Apparently money that has come out of tech stocks and money markets is going into healthcare stocks. In case you missed it even large cap drug stocks which have...
by Rod Raynovich | Apr 14, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Biotech stocks are up again today ignoring the overall weakness in tech stocks. Among the notable movers today are: Dendreon (DNDN $41.15) broke out above 40 up 5.5% on heavy volume with high expectations for the May 2 Conference call and presentation of data at ASCO...
by Rod Raynovich | Apr 12, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Biotechnology Sector Outperforming Within NASDAQ A torrid run-up of over 10% in biotech stocks over the past 3 weeks brings caution to mind as the NASDAQ sell-off hits 1%. Over the past 5 days the NASDAQ sell-off is 2% while biotech indices are only down 1%,...
by Rod Raynovich | Apr 12, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Exelixis (EXEL $12.17) has hired Goldman-Sachs to deal with potential takeover bids according to stories in Reuters and Bloomberg. Exelixis has a Phase III cancer drug XL184 (cabozantinab) and announced positive Phase 2 interim data for prostate cancer on Feb. 17....
by Rod Raynovich | Apr 11, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Biogen (BIIB $78.24) soared today on positive top line data on the Phase 3 Trial for oral BG-12 (dimethyl fumarate) as a montherapy in people with relapsing-remitting multiple sclerosis (RRMS). Results showed that 240 mg of BG-12 2x or 3x a day met the primary and...
by Rod Raynovich | Apr 8, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Reviewing Today’s Action A mixed market today with a slight edge to the bulls. Immunogen(IMGN $12.28) up 4% continues its run from yesterday on positive data from its collboration with Roche on T-DM1 (trastuzumab) an antibody coupled with a cell killing agent...
by Rod Raynovich | Apr 6, 2011 | 2024 Rayno Tools and Diagnostics Portfolio, 2024-25 Life Science Portfolios, BIOgraph
11/29/11 No new buys on tools/Dx since summer meltdown and Illumina (ILMN) miss. 6/20/11 NASDAQ (2632) Market stabilizing after 7% correction.QQQ down <1%. IBB up 10% YTD. Mid-cap biopharms are up 1.6% as of mid-day. Mixed tape in Dx and Tools with winners BLUD,...
by Rod Raynovich | Apr 5, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Dr. Mark Monane Senior Analyst of Biotechnology at Needham & Co. was on CNBC today giving a turbo boost to the biotech rally that began in mid-March. 100 companies are presenting at the Conference. Over the past 3 weeks the biotech sector is up almost 10%. Two...
by Rod Raynovich | Apr 4, 2011 | 2024-25 Life Science Portfolios, 2025 Rayno Biopharmaceuticals Portfolio, BIOgraph
11/18 Added Dendreon (DNDN) at $8.00 level.IBB is preferred biotech ETF. 11/15/11 Comments: Under review: ImmunoGen (IMGN) Dropped FBT an ETF in favor of IBB or possibly XBI. For bullish equity allocation in Tech and Biotech use QQQ. 6/20/11 NASDAQ (2632) Market...
